Andere Sprachen Nektar Therapeutics

Aktien

165417

US6402681083

NKTR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 18.04.2024			% 5 Tage	% 1. Jan.
1,3 ^USD	-3,70 %		-17,72 %	+130,09 %

05.03.	Nektar Therapeutics beginnt Phase 2b-Studie für Rezpegaldesleukin bei Patienten mit schwerer Alopecia Areata	MT
05.03.	NEKTAR THERAPEUTICS : Jefferies & Co. bekräftigt seine neutrale Bewertung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference	25.03.
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	22.03.
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	19.03.
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	05.03.
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	05.03.
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	05.03.
Nektar: Q4 Earnings Snapshot	04.03.
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	04.03.
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M	04.03.
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04.03.
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX	04.03.
North American Morning Briefing : Stock Futures -2-	04.03.
Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC	04.03.
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference	28.02.
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets	27.02.
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	22.01.
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA	04.01.
Nektar Therapeutics(NasdaqCM:NKTR) dropped from NASDAQ Biotechnology Index	15.12.
Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255	12.12.
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology Annual Meeting	12.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nektar Therapeutics

Aktien

165417

US6402681083

NKTR

Andere Sprachen

Filter